Business Wire

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

1.10.2024 10:15:00 EEST | Business Wire | Press release

Share

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) in patients with mild-to-moderate ulcerative colitis (M2M UC). These results have been published in the Journal of Clinical Medicine.1

UC is a chronic, inflammatory bowel condition which can cause recurring bloody diarrhoea, stomach pain and extreme tiredness.4 Of those living with UC, over 85% have mild-to-moderate disease.5,6,7 Usually 5-ASA compounds are the first-line therapy for people with M2M UC, followed by a stepwise treatment approach in case of non-response or intolerance. There is currently limited guidance on timely escalation and de-escalation of therapies.

OPTIMISE was the first major study to investigate whether a T2T approach based on monitoring of non-invasive parameters, such as clinical symptoms and FC, can provide a significantly higher benefit for patients with M2M UC versus an entirely symptom-based approach. “The OPTIMISE study represents another milestone in the management of M2M UC and demonstrates Ferring’s continued commitment to science and improving the lives of people with inflammatory bowel disease (IBD),” said Pierre-Yves Berclaz, Chief Science & Medical Officer, Ferring Pharmaceuticals.

Results from OPTIMISE, a pragmatic, randomised controlled study, showed that people who had their 5-ASA/mesalazine treatment optimised (with or without steroids) by following the T2T approach had a 17–22% advantage at achieving combined endoscopic and clinical remission over a symptoms-only based approach. For the primary endpoint of Mayo Endoscopic Score (MES)=0 at 12 months, no significant difference was found, however it was noted by the investigators that the COVID-19 pandemic negatively impacted the amount of evaluable data.1

“OPTIMISE has provided the first real-world evidence that a T2T approach can help people living with IBD to achieve long-lasting remission and have a greater quality of life,” said Kristine Paridaens, Senior Medical Director, Gastroenterology, Ferring Pharmaceuticals.

A T2T approach has been advocated by the International Organisation for the Study of IBD (IOIBD).In their Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Consensus they recommended resolution of clinical signs of disease activity and endoscopic remission as the optimal targets.2 This was further refined in STRIDE-II to include symptomatic relief and normalisation of serum and faecal markers as short-term targets for all therapies.3

The OPTIMISE results coincide with an international expert consensus focusing on the practical management of M2M UC, which was published in Expert Review of Gastroenterology and Hepatology.8 Professor Silvio Danese, a co-author of the Consensus and Principle Investigator of the OPTIMISE study, said, “The OPTIMISE study provides real-world evidence of the effectiveness of a T2T approach based on FC monitoring and how its implementation in clinical practice will allow clinicians to tightly monitor disease activity and promptly adapt treatment, helping to avoid complications and disease progression and enabling patients to achieve better disease control.”

To learn more, register here to attend the free ‘New avenues in mild-to-moderate UC treatment optimisation’ webinar on 8th October, 2024. Principal Investigators of the OPTIMISE study, Prof Silvio Danese and Prof Laurent Peyrin-Biroulet, will provide an expert overview of the results and the implications for clinical practice. The webinar is intended for healthcare professionals only.

About the OPTIMISE study1

OPTIMISE was a European-based, multi-centre, randomised (1:1) controlled study of 250 patients with M2M UC (global Mayo score 2–6) treated with ≤2.4g/day 5-aminosalicylic acid that compared the effectiveness of two management strategies with (T2T arm) and without (reference arm) FC home monitoring over 12 months follow-up. Treatment was optimised (escalated or de-escalated) in the T2T arm using FC values and clinical symptoms (PRO-2), whilst the reference arm used only PRO-2. In both arms, therapy was optimised in line with current ECCO guidelines for UC, including maximal doses of 5-ASA (oral and rectal).

A total of 193 patients completed the study despite the acknowledged impact of the COVID-19 pandemic on all clinical studies conducted during that time. Reduced patient contact during the COVID-19 period also affected the availability of data for analysis. For the primary endpoint of MES=0 at 12 months, there was no significant difference between arms, when patients with missing values were classified as non-responders. A subsequent analysis using Monte Carlo Markov Chain (MCMC) imputation found a numerical advantage for the T2T arm over the reference arm for the primary endpoint (37.0% vs 33.4%, respectively). The secondary endpoints, including clinical symptomatology and quality of life, were similarly impacted by missing data, but again displayed numerical superiority for MES≤1, RB=0 and SF≤1 at 12 months when using MCMC imputation.

A logistic regression analysis pooling results for MES, SF and RB at 12 months, using data derived from MCMC imputation, found a statistically significant advantage for the T2T arm over the reference arm (p<0.001). When these endpoints were combined in a fixed effects meta-analysis, the combined endpoint of MES=0, RB=0 and SF≤1 at 12 months was achieved at a significantly higher rate in the T2T than the reference arm (effect size [ES]: 0.17, 95% CI 0.02, 0.32; p<0.05). A similar result was obtained for MES≤1, RB=0 and SF≤1 at 12 months (ES: 0.22; 95% CI 0.07, 0.37; p<0.05).

References

1 Danese S, Fiorino G, Vicaut E, et al. Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis – the OPTIMISE study. J Clin Med 2024;13:5147.
2 Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324–38.
3 Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570–83.
4 NHS. Ulcerative colitis. Available at: https://www.nhs.uk/conditions/ulcerative-colitis/. Last accessed: September 2024.
5 Raine T, Bonovas S, Kucharzik T, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2-17.
6 Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. 2018;16(3):343-356.e3.
7 CCDS Pentasa All formulations. Version 18. 10 December 2022.
8 D'Amico F, Magro F, Dignass A, et al. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Rev Gastroenterol Hepatol 2024;18:421–30.

© 2024 Ferring. Ferring and the Ferring Pharmaceuticals logo are trademarks of the Ferring group of companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240930008755/en/

Contacts

Matthew Worrall
Director, Corporate Communications, Ferring
+44 7442 271 811
Matthew.Worrall@ferring.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 10:01:00 EET | Press release

Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advantage extends beyond outages to deployment, routine operations, and incident readiness. Concern reaches organiza

SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 10:00:00 EET | Press release

SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment architecture. GSOC is part of the DLR Space Operations and Astronaut Training institution in Oberpfaffen

Abbove Brings European Wealth Planning Into the AI Era18.11.2026 09:05:00 EET | Press release

Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors and their client families, it captures what aggregation alone cannot: goals, life events, gifts, the full picture of the family

Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 07:00:00 EET | Press release

Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global report features exclusive editions for the U.S., Canada, Europe, and APAC markets, offering region-specific i

Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 06:30:00 EET | Press release

Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is already taking shape, but scaling it requires more than innovation. Merchants need confidence in who they're transacting with, and payment providers need to know these transactions can move securely and reliably through existing infrastructure," said Rubail Birwadker, SVP, Growth Products & Partnerships, Visa. "No one company can solve tha

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye